My Portfolio
My Watchlists
Profile & Performance
Smart Portfolio
Find & Follow Experts
Top Lists
Top Experts
Make Better, Data Driven Investment Decisions
TipRanks tools are all you need to make data-driven investment decisions, conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts.
About Us
Plans & Pricing
Pacira Pharmaceuticals (PCRX)
NASDAQ:PCRX
PCRX nasdaq
United States
Pacira Pharmaceuticals

Pacira Pharmaceuticals Stock Analysis & Ratings

Pacira Pharmaceuticals Stock Analysis Overview

Smart Score
4
Neutral
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
The Pacira Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart

PCRX

PCRX Stock Stats

Previous Close$52.62
Open$53.73
Bid45 x 200
Ask60 x 100
Today’s Range$52.45 - $55.34
52-Week Range$45.05 - $80.00
Volume534.22K
Average Volume443.08K
Market Cap$2.37B
Beta0.97
P/E Ratio39.0
EPS1.35
Earnings DateFeb 24, 2022

Company Description

Pacira Pharmaceuticals

Pacira Biosciences, Inc. develops and manufactures injectable therapeutic products. The firm engages in the development, commercialization and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients. Its flagship product, EXPAREL, redefines pain management after surgery as an opioid-free alternative indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was founded in December 2006 and is headquartered in Parsippany, NJ.
Sector
Healthcare
Industry
Drug Manufacturers
CEO
David M. Stack
Employees
624
ISIN
US6951271005
Address
5 Sylvan Way, Parsippany, NJ, 07054, US

Financials


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

PCRX FAQ

What was Pacira Pharmaceuticals’s price range in the past 12 months?
Pacira Pharmaceuticals lowest stock price was $45.05 and its highest was $80.00 in the past 12 months.
    What is Pacira Pharmaceuticals’s market cap?
    Pacira Pharmaceuticals’s market cap is $2.37B.
      What is Pacira Pharmaceuticals’s price target?
      The average price target for Pacira Pharmaceuticals is $80.14. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $93.00 ,the lowest forecast is $57.00. The average price target represents 50.38% Increase from the current price of $53.29.
        What do analysts say about Pacira Pharmaceuticals?
        Pacira Pharmaceuticals’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 7 Wall Streets Analysts.
          When is Pacira Pharmaceuticals’s upcoming earnings report date?
          Pacira Pharmaceuticals’s upcoming earnings report date is Feb 24, 2022 which is in 84 days.
            How were Pacira Pharmaceuticals’s earnings last quarter?
            Pacira Pharmaceuticals released its earnings results on Nov 03, 2021. The company reported $0.72 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.07.
              Is Pacira Pharmaceuticals overvalued?
              According to Wall Street analysts Pacira Pharmaceuticals’s price is currently Undervalued.
                Does Pacira Pharmaceuticals pay dividends?
                Pacira Pharmaceuticals does not currently pay dividends.
                What is Pacira Pharmaceuticals’s EPS estimate?
                Pacira Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Pacira Pharmaceuticals have?
                Pacira Pharmaceuticals has 44,540,000 shares outstanding.
                  What happened to Pacira Pharmaceuticals’s price movement after its last earnings report?
                  Pacira Pharmaceuticals reported an EPS of $0.72 in its last earnings report, beating expectations of $0.65. Following the earnings report the stock price went up 4.94%.
                    Which hedge fund is a major shareholder of Pacira Pharmaceuticals?
                    Among the largest hedge funds holding Pacira Pharmaceuticals’s share is Paulson & Co Inc. It holds Pacira Pharmaceuticals’s shares valued at 71M.

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis